Anti-TMEM27 Antibody, Non-Fucosylated (BioBet-1361ZP) (CAT#: BioBet-1361ZP) Datasheet

TMEM27

transmembrane protein 27

This gene encodes a type 1 transmembrane protein that is important for trafficking amino acid transporters to the apical brush border of proximal tubules. The encoded protein binds to amino acid transporters and regulates their expression on the plasma membrane. It also plays a role in controlling insulin exocytosis by regulating formation of the SNARE (soluble N-ethylmaleimide-sensitive-factor attachment protein receptor) complex in pancreatic beta cells. The extracellular domain of the encoded protein may be cleaved and shed from the plasma membrane specifically in pancreatic beta cells.

TMEM27; transmembrane protein 27; NX17; NX-17; collectrin; kidney-specific membrane protein

Plasma membrane

Diseases associated with CLTRN include Aminoaciduria and Hartnup Disorder.

Its related pathways are Metabolism of proteins and Peptide hormone metabolism.

As the binding partner of amino acid transporters SLC6A18 and SLC6A19, it regulates its transport on the cell surface and amino acid transporter activity (similarity), and plays an important role in amino acid transport. It may also be involved in the transport of the amino acid transporters SLC3A1 and SLC7A9 to the renal cortex cell membrane (by similarity). Trap compound function regulator. Stimulator of cell replication.

1.Glycosylated. Glycosylation is required for plasma membrane localization and for its cleavage by BACE2 2.Modification sites at PhosphoSitePlus 3.Proteolytically processed in pancreatic beta cells by BACE2 leading to the generation and extracellular release of soluble CLTRN, and a corresponding cell-associated C-terminal fragment which is later cleaved by gamma-secretase. This shedding process inactivates CLTRN (By similarity). Three cleavage sites have been identified for BACE2, two clustered sites after Phe-116 and Leu-118 and a more membrane proximal site at Phe-125; the preferred BACE2 cleavage site seems to be between Phe-125 and Leu-126, Phe-116 and Leu-118 act as alternative sites 4.Glycosylation at Asn76 and Asn93

Protein Based Therapies
Monoclonal antibody (mAb)

IgG

BioBet-1361ZP

Humanized

Human

The antibody directed to the protein TMEM27 is used for the treatment of type II diabetes (T2D).

Type II Diabetes

Type II Diabetes